POTOMAC, Md., September 21, 2022–(BUSINESS WIRE)–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”

The original patent application was initiated by the University of South Florida (“USF”) and filed on July 30, 2015. On May 25, 2017, IGC entered into an exclusive license agreement with USF with respect to the patent application and the associated research conducted on Alzheimer’s disease. On January 9, 2020, the patent application was modified by the Company. Separately, on July 22, 2021, IGC announced the grant of the first patent (11,065,225) for some of that research and work. This new patent is for a continuation of that work.

The Company’s subsidiary, IGC Pharma, used some of the research to develop an oral formulation, IGC-AD1. Based on the USF research on Alzheimer’s cell lines, subject to further testing and clinical trials, testing indicates that on a dose dependent manner, the active agents in IGC-AD1 may ameliorate Aß plaque and decrease ptau, a phosphorylated protein responsible for tangles in neurons. Plaques and tangles are key hallmarks of Alzheimer’s disease. Further, testing in an Alzheimer’s mouse model showed that it improved memory as demonstrated in a Morris Water Maze test.

Based on these promising results, we initiated a Phase 1 study on safety and tolerability and in that study discovered that IGC-AD1 at specific dosing regimens had the potential to modify agitation and other neuropsychiatric symptoms in patients with Alzheimer’s dementia. Encouraged by this, our short term focus shifted to further testing IGC-AD1 as a therapeutic for treating neuropsychiatric synmptoms in Alzheimer’s, more specifically agitation. The Company recently filed a Phase 2 protocol with the U.S. Food and Drug Administration (“FDA”) for further clinical testing of the efficacy of IGC-AD1 on agitation in mild to severe Alzheimer’s.

Currently, there are no FDA approved pharmacological treatments for agitation in dementia from Alzheimer’s and about 70% of Alzheimer’s patients suffer from agitation/aggressiveness. The Company is hopeful that, subject to further trials and FDA approval, IGC-AD1 can provide relief for some of the over 55 million Alzheimer’s patients worldwide.

About IGC:

IGC has two segments: Life Sciences and Infrastructure. The Company is based in Maryland, U.S.A.

Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC’s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, and Quarterly Report on Form10-Q, filed with SEC on August 5, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005448/en/

Contacts

Claudia Grimaldi (301-983-0998)

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

• Market leadership – US patent recognizes and protects Micron’s biotechnology effluent treatment process to purify wastewater for government-compliant discharge or re-use
  
• Platform validation – Micron’s microbial and enzymatic waste digestion formulation has been validated in food and cannabis, and can be further modified for a wide range of bio-mass waste effluents, including those from spirits and brewing, bio-gas, food processing, pulp and paper, and biological drug manufacturing
  
• Licensing – Micron reserves the right to enter into exclusive licensing agreements with appropriate partners for sale, use and/or distribution of Micron’s patented formula as a wastewater effluent treatment

VANCOUVER and DELTA, BC, Jan. 17, 2019 /CNW/ – Micron Waste Technologies Inc. (“Micron” or the “Company”) (CSE: MWM, OTC: MICWF, Frankfurt: 7FM2), a leading developer of waste treatment systems for food and cannabis waste, has been awarded a United States Patent and Trademark Office (USPTO) patent for its commercial biological waste treatment formulation. US Patent 10,144,044 secures the intellectual property on the Company’s proprietary bio-process and compositions for the treatment of waste effluent. The patent recognizes and safeguards the innovative process developed by Micron’s Co-Founder and Chief Technology Officer, Dr. Bob Bhushan, whose research led to the development of “immobilization technology” to protect and enhance highly selective and effective microorganisms and enzymes. Dr. Bhushan’s advanced bio-process effectively allows effluent-degrading, GRAS¹-certified organisms to biodegrade organics inside Micron’s patented industrial-grade Cannavore cannabis and food waste digester units. The immobilization process protects the live agents, which activate with increased potency and enhanced metabolic activity.

“This is an important and validating milestone for Micron, locking in our leadership in a new era in organic waste management,” said Micron President and CEO Alfred Wong. “Dr. Bhushan’s formula complements the efficiency of our Cannavore and food waste digesters and can be used as an additive to boost the efficiency of other waste treatment systems, increasing their ability to comply with government regulations.”

Micron’s latest patent strengthens overall intellectual property protection for its innovative waste treatments systems. In July, 2018 the Company announced it was awarded an Industrial Design Certificate of Registration from the Canadian Intellectual Property Office (CIPO), with US patent pending, for its commercial digester units, which employ the newly-patented bio-agents and process. The units’ innovative, functional design enhances food digestion efficiency by up to 40% while reducing the machine’s footprint and digestion time. The technology was repurposed for use in the Cannavore, with the addition of proprietary conditioning agents to denature active pharmaceutical ingredients (APIs) in cannabis waste.

Micron’s first Cannavore is completing optimization at Aurora Cannabis Inc.’s (“Aurora”) (TSX: ACB) Mountain facility near Calgary. Subject to Micron’s technology meeting certain milestones per a collaboration agreement announced in December 2017, Aurora has committed to installing Micron’s technology at its other facilities.

The waste systems pulverize and render organic waste in combination with Micron’s live agent formula. Importantly, as part of Micron’s full-system waste treatment platform, effluent from the digester is further treated to derive clean greywater which can be re-used in growing operations or safely discharged.

The Micron Cannavore was engineered based on proven technology used by the Company in its food waste digester unit. The world’s first closed-loop cannabis waste processing system was designed to Aurora’s specifications to be a clean technology solution to process organic waste generated from the growth and cultivation of cannabis, while mitigating concerns about the potential environmental impact.

Micron’s waste management systems employ advanced computer science for remote real-time diagnostics monitoring and control. The mobile, comprehensive units – which do not emit sound or smell – are engineered to operate on-site within a 40 ft. shipping container, deployable on land or at sea, without need to truck, incinerate or landfill methane-producing waste.

Micron currently has additional Cannavore systems under construction, working with strategic partner BC Research Inc., with manufacturing completion targeted for the second quarter of 2019. Micron’s food waste system prototype is currently being upgraded with new technology developed for the Cannavore. Micron is also in the final commissioning phase of its R&D and manufacturing facility in Delta, BC.

Photo: Micron Waste Chief Technology Officer Dr. Bob Bhushan

About Micron Waste Technologies Inc.
Micron Waste Technologies Inc is a well-funded technology company with over $5.5 million in working capital. The Company’s organic waste management systems process waste directly on-site and treat the resulting wastewater to meet or exceed municipal sewage discharge standards. The purified water can be discharged directly into the sewer or recycled back into industrial or agricultural operations. The Company has developed the world’s first comprehensive cannabis waste management system. Please visit www.micronwaste.com for further information. Micron is a public company with listings on the CSE: MWM, OTC: MICWF, and in Frankfurt: 7FM2.

Alfred Wong
President and CEO

The Canadian Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

_______________________________
¹ GRAS or Generally Regarded as Safe under sections 201(s) and 409 of the US Federal Food, Drug, and Cosmetic Act

SOURCE Micron Waste Technologies Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2019/17/c9771.html

Karen Lauriston, VP Corporate, +1.905.691.1185, [email protected] CNW Group 2019